Therapeutic approaches in symptomatic hypertrophic obstructive cardiomyopathy

Revista Espanola de Cardiologia

Volumn 54, Issue 11, 2001, Pages 1311-1326

  Montijano Cabrera, A M ^a   Bouzas Zubeldía, Beatriz ^b   Penas Lado, Manuel ^c   McKenna, William J ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c Geriatric Service Hospital Ntra Sra de la Montaña Complejo Hospitalario de Cáceres   (Spain)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; NADOLOL; NIFEDIPINE; PLACEBO; VERAPAMIL;

AORTA SUBVALVULAR STENOSIS; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIENCE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PACING; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MINIMALLY INVASIVE SURGERY; MITRAL VALVE REPLACEMENT; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION; ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; PATIENT SELECTION;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; HUMANS; PACEMAKER, ARTIFICIAL; PATIENT SELECTION;

EID: 0034747360     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(01)76502-5     Document Type: Review

References (154)

1. Asymmetrical hypertrophy of the heart in young adults
2. Hypertrophic cardiomyopathy. The importance of the site and extent of hypertrophy. A review
3. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology ant therapy
4. Hypertrophic cardiomyopathy
5. Hypertrophic cardiomyopathy. Clinical spectrum and treatment
6. Miocardiopatía hipertrófica. Formas clínicas y manejo terapéutico
7. Hypertrophic cardiomyopathy
8. The management of hypertrophic cardiomyopathy
9. Hypertrophic cardiomypathy
10. Report of the 1995 World Heart Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies
11. Prevalence of hypertrophic cardiomyopathy in a population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study: Coronary Artery Risk Development in (Young) Adults
12. Estratificación del riesgo en la miocardiopatía hipertrófica
13. Identificación y tratamiento de los pacientes con miocardiopatía hipertrófica y riesgo de muerte súbita
14. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatients population
15. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features
16. Hypertrophic cardiomyopathy: Is a left ventricular outflow tract gradient a major prognostic determinant?
17. Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy
18. Guía de práctica clínica sobre miocardiopatías y miocarditis
19. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy
20. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis
21. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade
22. Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis
23. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol
24. Propranolol in management of muscular subaortic stenosis
25. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy
26. Long-term propranolol therapy in muscular subaortic stenosis
27. Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy measured by non-invasive techniques
28. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: An echographic study
29. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects
30. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration
31. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy
32. Treatment of hypertrophic obstructive cardiomyopathy with verapamil
33. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy
34. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil
35. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short- and long-term effects
36. Does verapamil improve left ventricular relaxation in patients with myocardial hypertrophy?
37. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy
38. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy
39. Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy
40. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status
41. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy
42. Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: Evaluation with exercise pulsed Doppler echocardiography
43. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy
44. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy
45. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy
46. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide
47. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration
48. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration
49. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy
50. Effects on left ventricular function of pindolol added to verapamil in hypertrophic cardiomyopathy
51. Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy
52. Occurrence and significance of progresive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy
53. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy
54. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis
55. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia
56. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia
57. Miocardiopatía hipertrófica asintomática. Argumentos a favor de su tratamiento
58. El tratamiento quirúrgico precoz de la miocardiopatía hipertrófica obstructiva sintomática. Argumentos a favor
59. The surgical management of obstructive cardiomyopathy
60. The treatment of muscular subaórtic stenosis
61. Operative treatment in hypertrophic subaortic stenosis: Techniques, and the results of pre- and post-operative assessment in 83 patients
62. Hypertrophic subaortic stenosis. Operative methods utilized to lelieve left ventricular otflow obstruction
63. Diffuse muscular subaortic stenosis: Surgical treatment
64. Surgical resection in idiopathic hypertrophic subaortic stenosis with a combined approach through aorta and left ventricle
65. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis
66. Symptomatic status and prognosis after operation for hypertrophic obstructive cardiomyopathy: Efficacy of ventricular septal myotomy and myectomy
67. Hypertrophic obstructive cardiomyopathy: Ten-to-21-year follow-up after partial septal myectomy
68. Surgical treatment of hypertrophic obstructive cardiomyopathy with special reference to complications and to atypical hypertrophic obstructive cardiomyopathy
69. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy: Late results up to twenty-five years
70. Hypertrophic obstructive cardiomyopathy
71. Results of surgery for hypertrophic obstructive cardiomyopathy
72. Current operative treatment of obstructive hypertrophic cardiomyopathy
73. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: Experience over 15 years
74. Septal myotomy-myectomy versus mitral valve replacement in hypertrophic cardiomyopathy: Ten year follow-up in 185 patients
75. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: A retrospective study
76. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy
77. Postoperative and long-term prognosis of myotomy-myomectomy for hypertrophic obstructive cardiomyopathy: Influence of associated mitral valve replacement
78. Comparison of ventricular septal surgery and mitral valve replacement for hypertrophic obstructive cardiomyopathy
79. Hypertrophic obstructive cardiomyopathy: Initial results and long-term follow-up after Morrow septal myectomy
80. Surgical management of obstructive hypertrophic cardiomyopathy: Early and late results
81. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy
82. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy
83. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy
84. Management of symptomatic hypertrophic obstructive cardiomyopathy: Long-term results after surgical therapy
85. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy
86. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow and myocardial metabolism in hypertrophic cardiomyopathy
87. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy
88. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy
89. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy
90. Septal myomectomy and mitral valve replacement for idiopathic subaortic stenosis: Short-and long-term follow-up
91. Hemodynamic findings in patientes with left bundle branch block after myectomy in hypertrophic obstructive cardiomyopathy (HOCM)
92. Aortic regurgitation: A common complication after surgery for hypertrophic obstructive cardiomyopathy
93. Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease
94. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy
95. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mital apparatus
96. Extended myectomy for hypertrophic obstructive cardiomyopathy
97. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle
98. Erfahrungen mit der schrittmacher dauerbehandlung bei patienten mit obstruktiver kardiomyopathie
99. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy
100. Permanent pacing as treatment for hypertrophic cardiomyopathy
101. Reducing left ventricular outflow tract obstruction in patientes with hypertrophic cardiomyopathy by pacing-induced interventricular septal preexcitation
102. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy
103. DDD pacing in hypertrophic cardiomyopathy: A multicentre clinical experience
104. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind cross-over study
105. Effects of permanent dual-chamber pacing on mitral regurgitation in hypertrophic obstructive cardiomyopathy
106. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: Acute Doppler echocardiographic and catheterization hemodynamic study
107. Effects of dual chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function
108. Obstructive myocardiopathic hypertrophy and sequential atrioventricular stimulation. Immediate results and long term follow-up. Seven years experience
109. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy
110. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)
111. Appraisal of dual chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgement?
112. Estimulación secuencial auriculoventricular en la miocardiopatía hipertrófica obstructiva. ¿Qué pacientes se benefician?
113. Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy: A clinical perspective in 2000
114. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy
115. Vorhofsynchrone ventrikelstimulation mit verkuvzker a.v. verzogerungszeit alstherapieprenzip der hypertrophischen obstruktiven kardiopyopathie
116. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy
117. DDD pacing in obstructive HCM
118. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study
119. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up
120. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy
121. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: A comparison of objective hemodynamic and exercise end points
122. Estimulación bicameral en la miocardiopatía hipertrófica obstructiva sintomática: Todavía demasiados interrogantes
123. Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy
124. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy
125. Transcoronary chemical ablation of ventricular tachycardia
126. L'effet aigu d'une occlusion coronarienne par ballonet de la dilatation transluminale
127. New treatment methods for patients with hypertrophic obstructive cardiomyopathy
128. Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal branch of the left coronary artery
129. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy
130. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients
131. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography
132. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute and 3-month follow-up in 25 patients
133. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy
134. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic cardiomyopathy
135. Long-term clinical follow-up of surgical myectomy for hypertrophic obstructive cardiomyopathy
136. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long-term follow-up of the first series of 25 patients
137. Long term follow-up of hypertrophic myopathy patients treated with non-surgical septal reduction
138. Acute and long-term results after transcoronary ablation of septum hypertrophy in hypertrophic obstructive cardiomyopathy
139. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up
140. Alcohol septal ablation in hypertrophic obstructive cardiomyopathy. The need for a registry
141. Changes in left ventricular diastolic function 6 months after non-surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
142. Decreased expression of tumor necrosis factor-á and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy
143. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
144. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment
145. Advances in molecular genetics and management of hypertrophic obstructive cardiomyopathy
146. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy
147. Electromechanical left ventricular behavior after non-surgical septal reduction in patients with hypertrophic obstructive cardiomyopathy
148. Five years of percutaneous transluminal septal myocardial ablation
149. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms
150. Multiple disease genes cause hypertrophic cardiomyopathy
151. Genotype: Phenotype correlations in hypertrophic cardiomyopathy
152. Hypertrophic obstructive cardiomyopathy
153. Medical and surgical therapy of hypertrophic cardiomyopathy
154. Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age